Vizsgálati helyszín
Kliniken Maria Hilf GmbH Moenchengladbach
Moenchengladbach, 41063, NémetországMég nincs intézményhez kötve
- 22futó vizsgálat
- 11lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 33 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis20 vizsgálat
- 2. fázis12 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Toboroz14 vizsgálat
- Lezárult11 vizsgálat
- Fut, nem toboroz8 vizsgálat
- Fő szponzor
- University Of Cologne3 vizsgálat
- Christian Buske2 vizsgálat
- Hoffmann-La Roche2 vizsgálat
- Mirati Therapeutics Inc.2 vizsgálat
- University of Heidelberg Medical Center2 vizsgálat
- és még 22
Futó vizsgálatok
Toboroz
PREFer
NCT06916416· 2. fázis· University Of Cologne· Forrás
Toboroz
Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants
2025-521762-99-00· 3. fázis· University Medical Center Hamburg-Eppendorf· Forrás
Toboroz
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· 3. fázis· Pfizer· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
NCT05099471· 2. fázis· Christian Buske· Forrás
Toboroz
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
NCT06102057· 2. fázis· TheraOp· Forrás
Fut, nem toboroz
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma
2023-505436-35-00· 3. fázis· Lysarc· Forrás
Toboroz
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial)
2023-507402-13-00· 3. fázis· Universitaetsklinikum Heidelberg AöR· Forrás
Toboroz
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
NCT06223711· 2. fázis· Universität des Saarlandes· Forrás
Toboroz
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
NCT06061094· 2. fázis· Goethe University· Forrás
Toboroz
Venetoclax in combination with Ibrutinib and Rituximab or conventional
chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients
with Mantle Cell Lymphoma.
2022-501808-96-00· 2. fázis· Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR· Forrás
Fut, nem toboroz
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
A phase II, open-label, single arm study to evaluate the efficacy of
Luspatercept in Erythropoiesis-stimulating agent naive lower-risk
MDS patients with or without ring sideroblasts who do not require
RBC transfusions
2024-516438-36-00· 2. fázis· Universitaet Leipzig· Forrás
Toboroz
Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody
NCT05045664· 3. fázis· Heidelberg University· Forrás
Fut, nem toboroz
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
NCT04603807· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by
daratumumab re-treatment at first relapse (GMMG-DADA)
2024-517761-17-00· 2. fázis· University Of Cologne· Forrás
Toboroz
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596· 2/3. fázis· Mirati Therapeutics Inc.· Forrás
Fut, nem toboroz
Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients
NCT04246684· 3. fázis· Prof. Dr. med. Claus Rödel· Forrás
Fut, nem toboroz
Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
NCT03620903· 2. fázis· Christian Buske· Forrás
Fut, nem toboroz
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
NCT03617731· 3. fázis· University of Heidelberg Medical Center· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek